NCT06309199 Prevalence of FGIDs and Probiotics Study
| NCT ID | NCT06309199 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chulalongkorn University |
| Condition | Functional Gastrointestinal Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 512 participants |
| Start Date | 2024-03-14 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 512 participants in total. It began in 2024-03-14 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants.
Eligibility Criteria
Inclusion Criteria: 1. Healthy and term (GA 37-41 weeks) infants 2. Appropriate weight for age 3. APGAR score more than 8 at 10 minutes of life 4. Normal physical examination 5. Mothers have no previous probiotics use Exclusion Criteria: 1. not willing to anticipate in the study 2. cannot come to follow-up until 1 year of age
Contact & Investigator
Yong Poovorawan, MD
STUDY DIRECTOR
Center of Excellence in Clinical Virology
Frequently Asked Questions
Who can join the NCT06309199 clinical trial?
This trial is open to participants of all sexes, aged 3 Days or older, up to 1 Year, studying Functional Gastrointestinal Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06309199 currently recruiting?
Yes, NCT06309199 is actively recruiting participants. Contact the research team at palittiya.s@chula.ac.th for enrollment information.
Where is the NCT06309199 trial being conducted?
This trial is being conducted at Bangkok, Thailand.
Who is sponsoring the NCT06309199 clinical trial?
NCT06309199 is sponsored by Chulalongkorn University. The principal investigator is Yong Poovorawan, MD at Center of Excellence in Clinical Virology. The trial plans to enroll 512 participants.